Browse Penn-owned technologies available for licensing.
EGFRvIII is a mutation in the Extracellular Growth Factor Receptor that frequently occurs in GBM tumors. Targeting EGFRvIII mutations is an emerging therapeutic strategy for GBM therapy, however knowing which patients’ tumors have these mutations and who will benefit from EGFRvIII targeted therapies is hard. Routine molecular profiling of solid tumors takes several weeks and requires relatively large amounts of starting tissue.
More rapid identification of EGFRvIII mutations will help doctors find appropriate patients for new EGFRvIII-targeting therapies and guide patient enrollment in clinical trials.
Because of the high sensitivity of digital PCR, the presence of EGFRvIII mutations can be detected from small amounts of starting tissue and heterogenous groups of cells. The performance of this assay was validated against next-generation sequencing in a pilot study using GBM tumor samples collected from 40 patients.